Normal View Dyslexic View

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.

3 May 2024
Randomized clinical trials General

Info
Copied!